Report of Foreign Issuer (6-k)
October 18 2016 - 07:37AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 17 October 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr M M Slaoui
|
b)
|
Position/status
|
Chairman, Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of
the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 13 October 2016 on ADSs held in the Company's US
Deferred Performance Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
$46.1526
|
244.955
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-10-13
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D E Troy
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of
the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 13 October 2016 on ADSs held in the Company's US
Deferred Performance Share Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
$46.1526
|
324.557
|
|
|
$46.1526
|
5.002
|
d)
|
Aggregated
information
|
329.559
|
|
Aggregated
volume Price
|
$46.1526
|
e)
|
Date
of the transaction
|
2016-10-13
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October
17, 2016
By: VICTORIA
WHYTE
----------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024